Article

Predictive correlation between the International Index of Erectile Function (IIEF) and Sexual Health Inventory for Men (SHIM): implications for calculating a derived SHIM for clinical use.

Weill Medical College of Cornell University-Department of Urology, New York, NY, USA.
Journal of Sexual Medicine (Impact Factor: 3.51). 09/2007; 4(5):1336-44. DOI: 10.1111/j.1743-6109.2007.00576.x
Source: PubMed

ABSTRACT Validated questionnaires are used to assess postoperative continence, sexual function, and other quality-of-life issues after radical prostatectomy. The International Index of Erectile Function (IIEF) is one such well-tested inventory that is routinely used. However, some centers use the Sexual Health Inventory for Men (SHIM) or the IIEF-6 to record erectile function, and comparison between the three can be difficult.
To define if there was a predictive correlation between IIEF (or IIEF-6) and SHIM, and to explore a strategy for the use of an abbreviated and rapid functional assessment of erectile function in patients.
Preoperative and postoperative IIEF questionnaires from the robotic prostatectomy program at our institution were included in the study. The total IIEF, IIEF-6, and SHIM scores were calculated and correlations between the three were sought. We also looked at the feasibility of using only two questions from the IIEF with an aim of calculating both the SHIM and IIEF scores.
The power to differentiate between patients with SHIM >or=22 from those with SHIM <or=21 for (i) the ratio allowing direct conversion of IIEF (or IIEF-6) to SHIM; and (ii) a two-question-based recalculation of SHIM.
Two hundred seventy-five questionnaires were available for review. If the total IIEF score is known, the IIEF-derived SHIM score can be calculated by dividing the total IIEF score by a factor of 2.8 and then rounding off to a whole number. Furthermore, we have shown that an abbreviated questionnaire using Q5 and Q15 of the IIEF can be used to calculate the SHIM scores (two-question-SHIM).
We described an easy way to calculate the SHIM score when the IIEF (or IIEF-6) score alone is known. The two-question model can be used for a rapid assessment of the patients' sexual function.

0 Bookmarks
 · 
136 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: Determining if a man has erectile dysfunction (ED) seems like an innocuous task. However, this seemingly straightforward determination is fraught with peril, especially when applied to the reporting of erectile function after prostate cancer treatment. Is the wide range in ED outcomes following prostate cancer treatment really due to inherent biologic variability, or are there biases or other factors at work confounding the data? The goal of this chapter is to detail the specific difficulties for the quantification of ED in the context of challenges inherent to all scientific research: optimization of a study’s internal and external validity. Only through the understanding of the factors that influence the quantification of ED can consistent, standardized outcomes be obtained to advance the field of study. KeywordsCancer of the prostate-Biostatics-Comorbidities for ED-ED measurement-Neuropraxia-Androgen ablation therapy
    12/2010: pages 127-150;
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Premature ejaculation (PE) is a common male sexual dysfunction. Advances in PE research have been hampered owing to a nonstandardized definition of PE, until the definition by the International Society of Sexual Medicine (ISSM) in 2009. Once the diagnosis of PE is established through a thorough history, a variety of medical therapies is available, including tricyclic antidepressants, selective serotonin reuptake inhibitors (SSRIs), centrally acting opiates, phosphodiesterase 5 inhibitors and topical desensitizing creams. Most of these treatments increase the intravaginal ejaculation latency time (IELT) and patient satisfaction scores, with the most convincing evidence for SSRIs and topical creams. Daily SSRIs such as paroxetine, although efficacious, do have a substantial and prolonged side effect profile. Dapoxetine, which is a on-demand SSRI, is the only licensed drug for the treatment of PE, increasing IELT by a factor of 2.5 to 3 with limited and tolerable side effects. In the near future, the topical aerosol PSD502 is due to be licensed for the treatment of PE, increasing IELT by up to a factor of 6 but having minimal local and negligible systemic side effects.
    Therapeutic Advances in Urology 10/2011; 3(5):211-22.
  • [Show abstract] [Hide abstract]
    ABSTRACT: PURPOSE: Here, we 1) establish erectile dysfunction (ED) as an often neglected but valuable marker of cardiovascular risk, particularly in younger and diabetic men; and 2) review evidence that lifestyle change, combined with informed prescribing of pharmacotherapies used to mitigate cardiovascular risk, can improve overall vascular health and sexual functioning in men with ED. MATERIALS AND METHODS: A PubMed search for articles and guidelines pertinent to relationships between ED and cardiovascular disease (CVD), cardiovascular and all-cause mortality, and pharmacotherapies for dyslipidemia and hypertension was performed. The clinical guidance presented incorporates the current literature and the expertise of the multi-specialty author group. RESULTS: Numerous cardiovascular risk assessment tools exist, but risk stratification remains challenging, particularly for those patients at low or intermediate short-term risk. ED has a predictive value for cardiovascular events that is comparable to or better than traditional risk factors. Interventional studies support lifestyle changes as means of improving overall vascular health as well as sexual functioning. Statins, diuretics, beta blockers, and renin-angiotensin system modifiers may positively or negatively affect erectile function. Furthermore, phosphodiesterase type 5 (PDE5) inhibitors used to treat ED may have systemic vascular benefits. CONCLUSIONS: Treatment of ED should be considered secondary to cardiovascular risk reduction, but informed prescribing may prevent worsening of sexual function in men receiving pharmacotherapy for dyslipidemia and hypertension. As the first point of medical contact for men with ED symptoms, the primary care physician or urologist has a unique opportunity to identify patients who require early intervention to prevent CVD.
    The Journal of urology 01/2013; · 4.02 Impact Factor